Nandrolone and Semax Interaction: Monitor | Peptide Database

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown. RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.

FDA-approved first-line treatment for excessive daytime sleepiness associated with narcolepsy. Significantly reduces unintended sleep episodes and improves the ability to sustain wakefulness throughout the day. FDA-approved for excessive sleepiness in individuals who work non-traditional hours (night shifts, rotating shifts). Taken 1 hour before the start of the work shift to maintain alertness during the shift. FDA-approved as adjunctive therapy for residual excessive daytime sleepiness in patients with obstructive sleep apnea who are already using CPAP but still experience daytime somnolence. Does not treat the underlying airway obstruction. Well-documented improvements in sustained attention, vigilance, and concentration during prolonged tasks. Benefits are most pronounced under conditions of sleep deprivation or fatigue, but also observed in well-rested individuals performing demanding cognitive work. Improvements in planning, decision-making, and cognitive flexibility observed across multiple studies. Effects are more consistent and reliable in sleep-deprived populations than in well-rested individuals. Modest improvements in working memory tasks, particularly in individuals experiencing fatigue or sleep deficit. Effects in well-rested, high-baseline individuals are less consistent. Used off-label for attention-deficit/hyperactivity disorder. Some studies show improvements in attention and impulsivity comparable to methylphenidate, though modafinil is not FDA-approved for this indication. FDA declined approval for pediatric ADHD due to skin reaction concerns. Investigated as an adjunct to antidepressants for treatment-resistant fatigue and cognitive symptoms in major depressive disorder. May improve residual sleepiness and cognitive dullness that persist despite adequate antidepressant response. Used off-label for fatigue associated with multiple sclerosis, one of the most disabling symptoms of the disease. Evidence is mixed, with some patients reporting meaningful improvement in energy and daily functioning.